STI571: A Paradigm of New Agents for Cancer Therapeutics
Publication: Journal of Clinical Oncology
Abstract
ABSTRACT: STI571 exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose selection, optimizing therapy, and predicting response, as are possible mechanisms of resistance to STI571. Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm to other malignancies are explored.
Get full access to this article
View all available purchase options and get full access to this article.
Information & Authors
Information
Published In
Copyright
© 2002 by American Society of Clinical Oncology.
History
Published in print: January 01, 2002
Published online: September 21, 2016
Authors
Metrics & Citations
Metrics
Altmetric
Citations
Article Citation
STI571: A Paradigm of New Agents for Cancer Therapeutics. JCO 20, 325-334(2002).
Download Citation
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
Download article citation data for:
Journal of Clinical Oncology 2002 20:1, 325-334
Journal of Clinical Oncology 2002 20:1, 325-334
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to get full access to it.
Subscribe
Subscribe to this Journal
Renew Your Subscription
Become a Member